Approved for through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Of

J.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

ımber.					PTCC O- 44 DOT OTO - O- O- IIIN - o-		
Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 28, 2004 (use as many sheets as necessary)				Complete if Known			
				Application Number	Unassigned		
				Filing Date	Concurrently Herewith		
				First Named Inventor	Yuji YAMAZAKI		
				Group Art Unit	Not yet assigned		
				Examiner Name	Not yet assigned		
Sheet	1	of	1	Attorney Docket Number	081356-0218		
		heets as ne	•	Examiner Name	Not yet assigned		

U.S. PATENT DOCUMENTS						
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
		-				

FOREIGN PATENT DOCUMENTS							
Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6		
A1	WO 02/076467	Genzyme Corporation	3/22/2002				
A2	WO 01/66595	Chiron Corporation & Kyoto University	3/7/2001				
А3	WO 01/66596	Chiron Corporation & Kyoto University	3/7/2001				
	No. ¹ A1 A2	Cite No.1 Foreign Patent Document Office3 Number4 Kind Code3 (if known) A1 WO 02/076467 A2 WO 01/66595	Cite No.¹ Foreign Patent Document Office³ Name of Patentee or Applicant of Cited Documents A1 WO 02/076467 Genzyme Corporation A2 WO 01/66595 Chiron Corporation & Kyoto University A3 WO 01/66596 Chiron Corporation & Kyoto	Cite No.1 Office3 Number4 Kind Code5 (if known) A1 WO 02/076467 Genzyme Corporation (University) A3 WO 01/66596 Chiron Corporation & Kyoto (Inc.) Amount Name of Patentee or Applicant of Cited Documents (Inc.) Date of Publication of Cited Document MM-DD-YYYYY A2 Genzyme Corporation (Inc.) 3/22/2002 (Inc.) 3/7/2001	Cite No.1 Office3 Number4 Kind Code5 (if known) A1 WO 02/076467 Genzyme Corporation A2 WO 01/66595 Chiron Corporation & Kyoto University A3 WO 01/66596 Chiron Corporation & Kyoto Office3 Number4 Kind Code5 (if known) Name of Patentee or Application of Cited Documents MM-DD-YYYY Only Cited Document MM-DD-YYYY On		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
1	A4	International Search Report	
	A5 _	Takashi SHIMADA et al., "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia", Proc. Natl. Acad. Sci., USA, 5/22/2001, Vol. 98, Issue 11, pp. 6500-6505.	
	A6 _	Yuji YAMAZAKI et al., "Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia", The Journal of Clinical Endocrinology & Metabolism, (11/2002), Vol. 87, No. 11, pp. 4957-4966.	
	A7	Yuji YAMAZAKI et al, "Detection of Circulating FGF-23 by Monoclonal Antibodies Against Recombinant Human FGF-23", Journal of the American Society of Nephrology, (9/2002), Vol. 13, (Program and Abstract Issue), pg. 499A.	
	A8	Takashi SHIMADA et al, "FGF-23 Is a Novel Humoral Factor Regulating Vitamin D Metabolism", Journal of the American Society of Nephrology, (9/2002), Vol. 13, (Program & Abstract Issue), pg. 28A.	
	A9	Takashi SHIMADA et al., "Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo", Endocrinology, (8/2002), Vol. 143, No. 8 pp. 3179-3182.	
	A10	-Yuji YAMAZAKI et al, "Development of the ELISA System Using Monoclonal Antibodies against FGF-23 and Demonstration of Increased Plasma Concentration of FGF-23 in Tumor-Induced Osteomalacia", ENDO, 2002, The Endocrine Society's 84 th Annual Meeting, Program & Abstract, pg. 66.	
1	A11	-Y. YAMAZAKI et al., "FGF-23 Protein is Present in Normal Plasma and Is Increased in Patients with Tumor-Induced Osteomalacia", (9/2002), The Journal of Bone and Mineral Research, Vol. 17, suppl. 1, pg. 159.	

Examiner Signature	Muliolo	Date Considered	1/3/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Instude copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.